Symbols / BIOCQ $0.00 +0.00% Biocept, Inc.

Healthcare • Diagnostics & Research • United States • PNK
BIOCQ Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO —
Exch · Country PNK · United States
Market Cap 525.00
Enterprise Value 4.96M
Income -30.61M
Sales 1.36M
FCF (ttm) -4.24M
Book/sh 0.12
Cash/sh 2.53
Employees 50
Insider 10d —
IPO Feb 05, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.00
PEG —
P/S 0.00
P/B 0.00
P/C —
EV/EBITDA -0.16
EV/Sales 3.65
Quick Ratio 1.52
Current Ratio 1.81
Debt/Eq 3,996.90
LT Debt/Eq —
EPS (ttm) -96.34
EPS next Y -1.38
EPS Growth —
Revenue Growth -89.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2023-04-17
Earnings (prior) 2023-04-17
ROA -51.65%
ROE -186.94%
ROIC —
Gross Margin 0.00%
Oper. Margin -10.38%
Profit Margin 0.00%
Shs Outstand 2.63M
Shs Float 2.49M
Insider Own 0.00%
Instit Own 0.00%
Short Float 0.57%
Short Ratio 0.05
Short Interest 15.00K
52W High 0.10
vs 52W High -99.80%
52W Low 0.00
vs 52W Low 100.00%
Beta 23.00
Impl. Vol. —
Rel Volume 0.66
Avg Volume 359.00
Volume 238.00
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.00
Price $0.00
Change 0.00%
About

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-29.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2022-12-31 2021-12-31
Total Revenue
25.86
-57.78%
61.25
Operating Revenue
25.86
-57.78%
61.25
Cost Of Revenue
28.44
-24.69%
37.76
Reconciled Cost Of Revenue
28.44
-24.69%
37.76
Gross Profit
-2.58
-110.99%
23.48
Operating Expense
29.40
+13.54%
25.89
Research And Development
6.16
+24.21%
4.96
Selling General And Administration
23.24
+11.02%
20.93
Selling And Marketing Expense
7.13
-14.34%
8.32
General And Administrative Expense
16.11
+27.74%
12.61
Other Gand A
16.11
+27.74%
12.61
Total Expenses
57.84
-9.14%
63.66
Operating Income
-31.98
-1227.65%
-2.41
Total Operating Income As Reported
-31.98
-1227.65%
-2.41
EBITDA
-30.24
-3340.39%
-0.88
Normalized EBITDA
-30.24
-3340.39%
-0.88
Reconciled Depreciation
1.66
+8.17%
1.53
EBIT
-31.90
-1224.03%
-2.41
Net Income
-32.09
-1036.23%
-2.82
Pretax Income
-32.21
-1093.48%
-2.70
Net Non Operating Interest Income Expense
-0.32
-8.97%
-0.29
Interest Expense Non Operating
0.32
+8.97%
0.29
Net Interest Income
-0.32
-8.97%
-0.29
Interest Expense
0.32
+8.97%
0.29
Other Income Expense
0.09
—
Other Non Operating Income Expenses
0.09
—
Tax Provision
-0.12
-200.00%
0.12
Tax Rate For Calcs
0.00
-98.56%
0.00
Tax Effect Of Unusual Items
0.00
0.00
Net Income Including Noncontrolling Interests
-32.09
-1036.23%
-2.82
Net Income From Continuing Operation Net Minority Interest
-32.09
-1036.23%
-2.82
Net Income From Continuing And Discontinued Operation
-32.09
-1036.23%
-2.82
Net Income Continuous Operations
-32.09
-1036.23%
-2.82
Normalized Income
-32.09
-1036.23%
-2.82
Net Income Common Stockholders
-32.09
-1036.23%
-2.82
Otherunder Preferred Stock Dividend
—
0.00
Diluted EPS
-56.70
-894.74%
-5.70
Basic EPS
-56.70
-894.74%
-5.70
Basic Average Shares
0.57
+14.74%
0.49
Diluted Average Shares
0.57
+14.74%
0.49
Diluted NI Availto Com Stockholders
-32.09
-1036.23%
-2.82
Line Item Trend 2022-12-31 2021-12-31
Total Assets
30.87
-48.90%
60.42
Current Assets
16.34
-64.23%
45.69
Cash Cash Equivalents And Short Term Investments
12.90
-55.32%
28.86
Cash And Cash Equivalents
12.90
-55.32%
28.86
Cash Financial
12.90
-55.32%
28.86
Receivables
2.15
-84.40%
13.79
Accounts Receivable
2.15
-84.40%
13.79
Gross Accounts Receivable
—
47.82
Allowance For Doubtful Accounts Receivable
—
-34.03
Inventory
0.76
-71.44%
2.65
Raw Materials
1.97
-30.07%
2.81
Finished Goods
0.04
-14.29%
0.04
Prepaid Assets
—
0.39
Other Current Assets
0.54
+37.60%
0.39
Total Non Current Assets
14.53
-1.32%
14.72
Net PPE
14.14
-0.88%
14.27
Gross PPE
19.47
+2.99%
18.90
Accumulated Depreciation
-5.32
-14.89%
-4.63
Properties
0.00
0.00
Buildings And Improvements
—
9.03
Machinery Furniture Equipment
7.17
+16.44%
6.16
Construction In Progress
0.04
-84.08%
0.24
Other Properties
11.57
-2.49%
11.87
Leases
0.69
+8.68%
0.63
Other Non Current Assets
0.39
-15.35%
0.46
Total Liabilities Net Minority Interest
22.01
-4.03%
22.94
Current Liabilities
5.51
-53.23%
11.77
Payables And Accrued Expenses
2.97
-68.04%
9.30
Payables
1.52
-78.98%
7.25
Accounts Payable
1.52
-78.98%
7.25
Current Accrued Expenses
1.45
-29.51%
2.06
Pensionand Other Post Retirement Benefit Plans Current
0.80
-16.86%
0.96
Current Debt And Capital Lease Obligation
1.73
+14.91%
1.51
Current Debt
0.12
—
Other Current Borrowings
0.12
—
Current Capital Lease Obligation
1.62
+7.16%
1.51
Total Non Current Liabilities Net Minority Interest
16.51
+47.86%
11.16
Long Term Debt And Capital Lease Obligation
10.38
-7.07%
11.16
Long Term Capital Lease Obligation
10.38
-7.07%
11.16
Other Non Current Liabilities
6.13
—
Stockholders Equity
8.86
-76.36%
37.48
Common Stock Equity
8.86
-76.36%
37.48
Capital Stock
0.00
+0.00%
0.00
Common Stock
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
Share Issued
0.57
+1.31%
0.56
Ordinary Shares Number
0.57
+1.31%
0.56
Additional Paid In Capital
307.30
+1.14%
303.83
Retained Earnings
-298.44
-12.05%
-266.35
Total Equity Gross Minority Interest
8.86
-76.36%
37.48
Total Capitalization
8.86
-76.36%
37.48
Working Capital
10.84
-68.05%
33.92
Invested Capital
8.98
-76.05%
37.48
Total Debt
12.11
-4.45%
12.67
Capital Lease Obligations
11.99
-5.37%
12.67
Net Tangible Assets
8.86
-76.36%
37.48
Tangible Book Value
8.86
-76.36%
37.48
Inventories Adjustments Allowances
-1.24
-518.91%
-0.20
Line Item Trend 2022-12-31 2021-12-31
Operating Cash Flow
-13.29
-460.14%
3.69
Cash Flow From Continuing Operating Activities
-13.29
-460.14%
3.69
Net Income From Continuing Operations
-32.09
-1036.23%
-2.82
Depreciation Amortization Depletion
1.66
+8.17%
1.53
Depreciation
1.66
+8.17%
1.53
Depreciation And Amortization
1.66
+8.17%
1.53
Other Non Cash Items
0.62
-43.81%
1.11
Stock Based Compensation
3.23
+31.07%
2.46
Provisionand Write Offof Assets
—
0.11
Operating Gains Losses
0.01
+125.00%
0.00
Gain Loss On Sale Of PPE
0.01
+125.00%
0.00
Change In Working Capital
13.29
+841.53%
1.41
Change In Receivables
11.64
+3150.28%
0.36
Changes In Account Receivables
11.64
+3150.28%
0.36
Change In Inventory
1.89
+362.69%
-0.72
Change In Prepaid Assets
0.69
+37.23%
0.51
Change In Payables And Accrued Expense
-6.63
-1088.17%
-0.56
Change In Accrued Expense
-0.77
-423.81%
-0.15
Change In Payable
-5.86
-1325.79%
-0.41
Change In Account Payable
-5.86
-1325.79%
-0.41
Change In Other Working Capital
—
1.86
Change In Other Current Assets
0.03
+196.55%
-0.03
Change In Other Current Liabilities
5.66
0.00
Investing Cash Flow
-0.81
+48.66%
-1.57
Cash Flow From Continuing Investing Activities
-0.81
+48.66%
-1.57
Net PPE Purchase And Sale
-0.81
+48.66%
-1.57
Purchase Of PPE
-0.81
+48.66%
-1.57
Capital Expenditure
-0.81
+48.66%
-1.57
Financing Cash Flow
-1.87
-115.12%
12.38
Cash Flow From Continuing Financing Activities
-1.87
-115.12%
12.38
Net Issuance Payments Of Debt
-1.30
-13.48%
-1.15
Repayment Of Debt
-1.30
-13.48%
-1.15
Long Term Debt Payments
-1.30
-13.48%
-1.15
Net Long Term Debt Issuance
-1.30
-13.48%
-1.15
Net Common Stock Issuance
0.24
-98.30%
14.12
Proceeds From Stock Option Exercised
0.00
-100.00%
0.03
Net Other Financing Charges
-0.81
-29.58%
-0.62
Changes In Cash
-15.97
-210.15%
14.50
Beginning Cash Position
28.86
+100.89%
14.37
End Cash Position
12.90
-55.32%
28.86
Free Cash Flow
-14.10
-765.53%
2.12
Interest Paid Supplemental Data
0.32
+8.97%
0.29
Income Tax Paid Supplemental Data
—
0.00
Common Stock Issuance
0.24
-98.30%
14.12
Issuance Of Capital Stock
0.24
-98.30%
14.12
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category